## **Core Concept**
Medullary thyroid cancer (MTC) is a type of thyroid cancer that originates from the parafollicular cells, also known as C cells, which produce calcitonin. This cancer can occur sporadically or as part of hereditary syndromes such as Multiple Endocrine Neoplasia (MEN) 2A and 2B. MTC does not arise from the follicular epithelial cells, which are the origin of other thyroid cancers.

## **Why the Correct Answer is Right**
The correct answer relates to the characteristic features and behaviors of medullary thyroid cancer. MTC is known for producing calcitonin, and elevated calcitonin levels are a diagnostic marker. It does not concentrate iodine, which is a feature shared by well-differentiated thyroid cancers (papillary and follicular thyroid cancers) that can be treated with radioactive iodine. MTC can occur in familial forms associated with genetic mutations.

## **Why Each Wrong Option is Incorrect**
- **Option A:** If the statement suggests MTC originates from follicular cells, it is incorrect because MTC originates from parafollicular C cells.
- **Option B:** If the statement implies MTC does not produce calcitonin, it is incorrect because elevated calcitonin levels are a hallmark and diagnostic marker for MTC.
- **Option C:** Without the specific content of option C, we cannot directly address its accuracy. However, any statement contradicting known facts about MTC (such as its cell origin, calcitonin production, familial occurrence, or response to treatments) would be incorrect.
- **Option D:** Similarly, without the content, we assess based on common misconceptions. If it suggests MTC responds well to radioactive iodine, it would be incorrect because MTC cells do not take up iodine due to their parafollicular cell origin.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl for medullary thyroid cancer is that **elevated calcitonin levels are a specific tumor marker** for MTC. This fact is crucial for diagnosis and follow-up. Additionally, genetic screening for RET proto-oncogene mutations is recommended for familial MTC and MEN syndromes.

## **Correct Answer: D.**